Please login to the form below
gemcitabine
This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.
Merck chases Roche with triple-negative breast cancer data for Keytruda
The actual progression-free survival (PFS) numbers for KEYNOTE-355 – which compared Keytruda plus Bristol-Myers Squibb/Celgene’s Abraxane (nab-paclitaxel), paclitaxel or gemcitabine/carboplatin to the chemo drugs given
Latest news
-
Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial
after first-line gemcitabine-based treatment.
-
Keytruda monotherapy fails in triple negative breast cancer
By contrast, Merck &Co’s phase 3 Keynote-119 trial evaluated Keytruda as a monotherapy for the second or third-line treatment compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine). ... One such study is Keynote-355, which looks
-
Celgene’s Abraxane fails pancreatic cancer trial
Expectations for a positive outcome for the trial weren’t high, particularly as it used gemcitabine as a control. ... Since APACT was started, a new regimen called mFOLFIRINOX – based on oxaliplatin, leucovorin, irinotecan, and fluorouracil – has
-
CTI slumps as Servier-partnered lymphoma drug fails
gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS), its primary endpoint.
-
NICE knocks-back Shire's pancreatic cancer drug Onivyde
The watchdog was reviewing the treatment’s use in England and Wales for metastatic pancreatic cancer that has progressed after gemcitabine-based therapy.
More from news
Approximately 1 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
The rise of chronic disease in BRIC markets
For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Battling breast cancer with precision medicine (Part 2)
I wanted her to access the best treatment possible. I also knew that carboplatin was especially effective when used with another chemotherapy called gemcitabine, as the two drugs are known to ... tested the PARP inhibitor with the gemcitabine-carboplatin
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
Unfortunately, recurrence rates in high-grade ovarian cancer mean that platinum resistance is a very real possibility, leaving second-line treatment such as gemcitabine, topotecan or liposomal doxorubicin less effective over
-
Marketing strategy in complex environments
cells. A good example of this is the combined use of Abraxane and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and ... gemcitabine encourages apoptosis of cell
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- Sinovac’s COVID-19 vaccine appears safe in older adults
- bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
